InBrain Pharma is a biotech start-up, spin-off from the U1171 laboratory, developing innovative solutions against neurodegenerative diseases. Faced with the lack of solutions for the patients and given of promising research results, the InBrain Pharma team is committed to offer new treatments to patients
The brain is a special organ which requires a specific care-management. Indeed, oral treatments are problematics and cause many side effects due to their diffusion to the whole body, whereas only the brain is targeted.
Moreover, the efficacy of oral treatments is often limited by the dose and the short administration time. Also, many therapeutic solutions do not pass the digestive barrier and the blood-brain barrier.
On the other hand, controlled administration in the central nervous system allows a precise, continuous and targeted administration directly into the brain, increasing the efficacy and safety of treatments, particularly for severe diseases of the central nervous system.
InBrain Pharma is developing this concept of Brain Infusion.
Neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS)... represent a major challenge for our society. They affect millions of patients and inexorably progress inexorably towards disability and death without treatmentcapable of slow this progression and bring catastrophic socio-economic consequences.
Parkinson's disease is linked to the degeneration of dopaminergic neurons in the black substance. It is the second most common neurodegenerative disease with 6,500,000 patients worldwide and 1-2% of the population over 65 years of age affected. The disease is manifested by akinesia, tremors, rigidity, postural instability and many other non-motor signs (depression, anxiety, pain, intellectual and behavioural disorders, etc.).
Dive : Parkinson's disease treatment
Dive's therapeutic innovation consists in continuously administering the missing dopamine into the brain of patients with Parkinson's Disease, particularly at the advanced stage of complications related to oral dopamine treatment (L-dopa).
At this stage, therapeutic alternatives are often proposed. These alternatives are invasives, not very ergonomics friendly or doesn't control gait and speech disorders as well as emotional disability. The DIVE technique will significantly improve motor disability and quality of life without altering walking, speech and emotional disability. This approach of continuous compensation of missing dopamine is made possible thanks to our new technology of natural dopamine preparation limiting the dopamine oxidation. This therapeutic innovation will be to parkinsonians what the insulin pump is to diabetics.
Academic and private :
InBrain Pharma has partnerships with :
- The labolatory U1171 specialized in the treatment of degenerative and vascular cognitive disorders of the University of Lille, CHRU of Lille, INSERM
- The labolatory EA7365 specialized in the administration of injectable drugs of the University of Lille.
- Tricumed : German manufacturer of Siromedes pumps.
- Flowonix : American manufacturer of Prometra pumps.
The team has already proven itself individually and collectively and has been carrying this project for 6 years.
David Devos, MD, PhD
preclinical scientific advisor
Professor of medical pharmacology, Neurologist at the university Lille, Inserm, University Hospital Center of Lille
He participated 260 publications.
He conducted 28 clinical trials including 15 multi-centre trials, including one European trial and 14 as coordinator.
He obtained the Health Professionals Competition prize Eurasanté 2015 "from test tube to patient", the European Pharmacology Prize 2013 and the French Medical Pharmacology Prize Patrick Jaillon in 2013.
Matthieu Fisichella, PhD
Doctor-Engineer in Biology
Previously, project manager in biology/health at SATT Nord (Lille), his mission was to detect and manage innovative projects.
In 5 years, he detected more than 55 technologies, evaluated and set up 10 projects, obtained and managed more than 2 million euros of budget.
Caroline Moreau, MD,PhD
preclinical scientific advisor
University lecturer in Neurology, University of Lille, Inserm, CHU of Lille.
She counts 81 articles, participated in 17 clinical trials which included 10 multicentre studies including one European and 3 as coordinator.
Assistant secretary of the SFN since 2016.
French representative's at the EAN.
In house legal counsel
With its experience in the international groups Promod and Damartex, and in the pharmaceutical group Macopharma,
She deals in particular with national and international contracts, corporate law and issues related to public health law.
Biotech project manager
With a master's degree in Pharmacy and specialized in Market Acess, he joined us to develop our new technologies and ensure regulatory compliance.
Fondation of the Univeristy of Lille
Created at the end of 2014 with an initial endowment of €15 million, the Fondation of the University of Lille combines the flexibility and agility inherent with its status as a legal entity under private law with a strong vocation to support excellence in training and research, to develop pedagogical, technological and scientific innovation and to contribute to the influence and attractiveness of the University of Lille. It is thus the agency of means at the service of the University of Lille's ambition for excellence. The Foundation is also perfectly integrated into its ecosystem, since the President of the European Metropolis of Lille, the President of the MEDEF Hauts-de-France and the General Director of the Lille University Hospital are members of its Board of Directors.
FINOVAM GESTION manages €50 million through two funds for a portfolio of 28 companies in the "Hauts-de-France" and "Grand-Est" regions. FIRA NORTD-EST aims to enable the emergence of companies with high growth potential in cutting-edge sectors in the North-East quarter of France. FIRA NORD-ESTT invests from €300 K to €2.5 M per project.
The fund has the support of the Hauts-de-France and Grand-Est Regional Councils alongside BNP Paribas, Crédit Agricole Nord de France, Crédit Agricole Brie Picardie, Crédit Agricole de Lorraine, Caisse d'Epargne Hauts-de-France, Caisse d'Epargne Lorraine Champagne-Ardenne, and Adeo, Lesaffre and Tereos Groups, and privete investors.
Nord France Amorçage
created in February 2013, Nord France Amorçage is today a 30 million euro fund. It is fully owned by the Region, which mobilises FEDER funds to the amount of €21.5 million to provide equity capital to innovative regional SMEs.
This fund is part of the Research and Innovation Strategy and aims to provide better support and funding for innovation. It is managed by the Siparex Group, an independent specialist in private equity for SMEs.